Filtered By:
Specialty: Medical Devices
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
EnGeneIC wins orphan drug designation for targeted nanocells
EnGeneIC said today that the FDA granted orphan drug designation to the company’s targeted EDV nanocells for the treatment of glioblastoma multiforme.
The clinical stage biopharmaceutical company is developing bacterially-derived EDV nanocells as a nanoparticle, siRNA and miRNA delivery platform designed to target and kill tumor cells, while triggering the immune system’s natural anti-tumor response.
Get the full story at our sister site, Drug Delivery Business News.
The post EnGeneIC wins orphan drug designation for targeted nanocells appeared first on MassDevice.
Source: Mass Device - March 2, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Regulatory/Clearance Wall Street Beat EnGeneIC Source Type: news
